Evidence
Improved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
October 15, 2025Clinical Outcomes Article / Publication
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn MoreOctober 3, 2025Clinical Outcomes Article / Publication
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Improved A1c in People with Noninsulin Treated-T2D Using CGM in Primary Care: The Dexcom Global Registry
Dexcom G7 was associated with significantly improved A1c at 3 and 6 months, reduced body weight and BMI at 3 months, and improved TIR, TAR, and mean glucose at months 2 through 6 (p<0.05). This evidence supports updated standards of care that recommend consideration of CGM use in people with T2D not on insulin.
Learn MoreDexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
October 15, 2025Clinical Outcomes Article / Publication
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn MoreOctober 3, 2025Clinical Outcomes Article / Publication
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Dexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)
Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.
Learn MoreOctober 3, 2025Clinical Outcomes Article / Publication
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
In a large national federal cohort, initiation of CGM was associated with lower mortality in patients with type 2 diabetes (T2D) using insulin. Risk for mortality was lower in CGM users, as were risks for all-cause hospitalization, cardiovascular events, and admissions for hyperglycemia. These findings suggest that CGM may offer benefits beyond glycemic control, even for patients with T2D receiving less intensive treatment.
Learn MoreSeptember 8, 2025Coverage and Benefit Design InfographicSeptember 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
September 8, 2025Population Health Article / Publication
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations by addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
Learn MoreAugust 7, 2025Population Health Article / Publication
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
This article addresses significant disparities in diabetes care within the United States, focusing on the underdiagnosis, undertreatment, and worse health outcomes experienced by minority populations, particularly Black and Hispanic individuals. It highlights the underutilization of Continuous Glucose Monitors (CGMs), a technology proven to improve diabetes management, despite clinical and economic benefits. The authors identify barriers to equitable access to CGMs, including high costs, insurance coverage limitations, and provider-level biases that result in less frequent discussions of this technology with minority patients. Finally, the writers propose policy changes by both private and public insurers and the increased promotion of patient education programs as crucial steps to reduce these disparities and enhance diabetes care for all.
Click here to watch the accompanying videos.
April 21, 2025Clinical Outcomes Article / Publication
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Among semaglutide users with T2D, use of CGM was associated with greater decreases in A1c compared to non-CGM users, regardless of insulin therapy. Reductions in A1c were greater for CGM users (-0.85%) compared to the control group (-0.29%) in the overall cohort (differences-in-differences (DID), -0.55%, P<0.0001). The proportion of CGM and semaglutide users who met the ADA target of A1c <7% nearly doubled compared to baseline. The proportion of CGM and semaglutide users who met the HEDIS target of A1c <8% increased by more than 50% compared to 12% for non-CGM users. These results suggest an additive effect of CGM and semaglutide, and their combined use could help more people with T2D reach their glycemic targets. The possible mechanisms underlying the additive benefit between CGM and semaglutide could include improved diabetes management self-efficacy (related to diet, exercise, and medication adherence) and more effective medication titration. CGM may enhance patient understanding and management of T2D, including those on GLP-1s.
Learn MoreApril 21, 2025Clinical Outcomes Article / Publication
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn More
April 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
CGM use was associated with -0.62% A1c reduction at 3 months in people with diabetes on basal only or non-insulin therapies in the primary care setting. CGM use significantly improved glycemic control in T2D patients irrespective of treatment regimen (non-insulin or basal insulin). This study was conducted in collaboration with the American Medical Group Association (AMGA).
Learn MoreApril 15, 2025Clinical Outcomes CGM Best Practices / Interview
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Expert: Juan Espinoza , MD, Chief Research Informatics Officer, Ann & Robert H. Lurie Children’s Hospital of Chicago NCQA Panel Committee Member, Diabetes Digital Technologies Roundtable participant (NCQA and ADA), NCQA Health Innovation Summit presenter
Summary: As CGM technology has revolutionized diabetes management, NCQA has recognized a need for more sophisticated measures to assess diabetes care quality. Since integrating the glucose management indicator (GMI) into their HEDIS measure set for 2024, NCQA and other key opinion leaders are looking at integrating further sophisticated metrics from CGM in the future. In this expert interview, Dr. Juan Espinoza shares key insights around the latest considerations on quality improvement in diabetes care relative to CGM-exclusive metrics. Having conducted years of research in the diabetes technology and quality space, Dr. Espinoza discusses evolving quality measures and their potential to advance diabetes management by incorporating a more comprehensive approach. In addition, he provides an overview of the value realized by payers and providers from integration of CGM data directly into the electronic health record.
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
April 8, 2025Coverage and Benefit Design Article / Publication
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More
Experts Recommend Integration of CGM in Payer Diabetes Management Programs and Risk-Sharing Agreements with Providers
An expert panel of 4 payer and 6 provider stakeholders was convened to discuss opportunities for CGM-based care management in risk-sharing agreements between payers and providers. The panelists were surveyed before 2 virtual roundtable meetings, during which pertinent clinical and trend data were shared.
All payer participants cited using interdisciplinary care management for type 2 diabetes (T2D) and 50% used a digital health platform, but only 25% featured an integrated CGM component. All payer participants responded that “fingerstick” glucose management was either inadequate or questionable for use in current care management programs for T2D. Conversely, 100% also responded that CGM would improve their care delivery solutions. These findings were published as an abstract in the Journal of Managed Care and Specialty Pharmacy and presented in a poster at the 2025 Academy of Managed Care Pharmacy Annual Meeting, including parameters for optimizing risk-sharing agreements incorporating CGM. Specifically, the expert panelists outlined 3 key elements of risk-sharing agreements: agreement design, realistic outcomes measures, and strategies to facilitate payer and provider participation. The recommendations provided by the panel may be valuable for managed care and payer decision makers in shaping risk-sharing agreements to advance the utilization of CGM and improve member outcomes in the management of T2D.
Albright J, McCormick D, Pourarsalan H, Pangrace M. Payer-Provider Risk-Sharing Agreements to Advance Continuous Glucose Monitoring–Based Care in Type 2 Diabetes. Presented at the AMCP Annual Meeting; Houston, TX: April 2, 2025. [Poster E6.]
Learn More